outcome. cTfh were longitudinally analyzed in a prospective cohort of patients (n = 206), pre-and posttransplantation. Clinical data, HLA sensitization, and cTfh function were recorded. Both pretransplant and 6-month posttransplant cTfh were able to derive IgG-producing plasmablasts. Pretransplant cTfh was decreased in patients, especially in those who received dialysis. However, these cells were increased in patients with previous allograft or transfusions and in HLA-sensitized recipients. After transplantation cTfh expanded, significantly more in patients who developed de novo anti-HLA antibodies than in patients who remained unsensitized. Augmented pretransplant cTfh positively correlated with higher intensity of pretransplant anti-HLA class I and with de novo anti-HLA class I and anti-HLA class II antibodies. Consistently, pretransplantation cTfh were higher in patients who experienced acute rejection (HR = 1.14 [1.04-1.25] ). Thus, we show a role for Tfh in anti-HLA sensitization and rejection.
Multicenter studies with additional patient cohorts are needed to validate these results. Immunosuppressive drugs targeting Tfh could be useful to improve outcomes.
K E Y W O R D S
kidney transplantation, HLA sensitization, circulating Tfh, acute rejection Follicular helper T cells (Tfh) are specialized in assisting B cell differentiation into plasma cells and are required for the efficient production of antibodies. 6, 7 Peripheral CD4+CXCR5+ T cells are considered cTfh and counterparts of the Tfh found in the germinal centers of secondary lymphoid organs. 8 In the study by He et al, circulating CD4+CXCR5+PD1hiCCR7lo T cells represented active Tfh differentiation in lymphoid organs and correlated with the production of protective antibodies after infection and vaccination and with the production of pathogenic antibodies in autoimmune diseases. 9 cTfh have been found to promote humoral responses in healthy volunteers and HIV+ patients receiving the flu vaccine. 9-11 cTfh levels were also increased in HIV+ patients who produced high titers of anti-HIV neutralizing antibodies 12 and in lupus patients, in particular those with greater disease severity and higher titers of ANA and anti-dsDNA autoantibodies. 13, 14 Given the essential role of Tfh in mounting the humoral response, it is plausible to speculate that, in the context of transplantation, Tfh direct the B cell-dependent alloreactivity for the production of anti-HLA antibodies and may be associated with ABMR and graft loss.
In limited series of recipients, increased cTfh were observed before the development of de novo DSA, 15 in association with chronic rejection, 16 or after transplantation in DSA-positive patients. 17 In an in vitro alloantigen setting, plasmablast differentiation and immunoglobulin production were both dependent on IL-21-producing cTfh. 18 Nevertheless, the relationship between cTfh and anti-HLA Here we observed that cTfh from end-stage renal disease (ESRD) and transplanted patients were capable of transforming B cells into immunoglobulin-producing plasmablasts. cTfh were augmented in recipients with past contact with alloantigens, and a progressive expansion of the cTfh pool was observed after transplantation. The increase in cTfh was significantly higher among pretransplant sensitized patients and in transplanted patients who developed de novo anti-HLA antibodies and a correlation existed between cTfh counts and the amount of anti-HLA antibodies. Taken together, our findings provide evidence of the role of Tfh in the production of anti-HLA alloantibodies in renal transplant recipients. Consistently, higher pretransplant cTfh counts emerged as a risk factor for acute rejection.
| MATERIAL S AND ME THODS

| Study population
We included all renal transplant recipients between November 2014
and June 2016 at Hospital 12 de Octubre (N = 206). This cohort was prospectively followed for one year posttransplantation, and clinical and immunological data were collected. Only for-cause biopsies for suspected rejection were performed. Rejections were defined as biopsy-proven acute rejection (BPAR) according to the 2015 Banff classification. 19 All patients signed a written informed consent. The study (PIE13/00045) was approved by the institutional medical ethical committee.
| Flow cytometry
cTfh were prospectively measured on fresh peripheral blood mononuclear cells at pretransplantation and at day 7, day 14, and CD3 PE-Cy7, CD4 FITC, CXCR5 APC, CD19 PE, CD27 APC-H7, and CD38 FITC (BD). Dead cells were excluded using DAPI (Sigma).
Immunoglobulin G (IgG) was measured in the collected supernatants by a sandwich enzyme-linked immunosorbent assay. and acute rejection, the number of days from transplantation to rejection was taken into account. Cox regression was used to estimate the impact of pretransplant cTfh on rejection, and hazard ratio was calculated with 95% confidence interval. Statistical analysis was performed using Stata 13.0 and SAS 9.3. P < .05 was considered statistically significant. Table 1 shows the main characteristics of the studied cohort. The median age was 56 and most patients were male, on dialysis, and 
| Detection of anti-HLA antibodies
| Statistical analysis
| RE SULTS
| Characteristics of the recipient cohort
| Circulating CD4+CXCR5+ T cells differentiate B cells into IgG-producing plasmablasts
We first tested whether the peripheral blood CD4+CXCR5+ T Figure 1D ). We therefore showed that the circulating CD4+CXCR5+ cells we measured in peripheral blood are functionally similar to Tfh cells, and can be referred to as cTfh. Circulating plasmablasts were barely detectable in peripheral blood from healthy controls (data not shown).
| cTfh are reduced in ESRD subjects and in patients receiving dialysis
The proportion of cTfh was significantly decreased in ESRD patients when compared to healthy controls (5.1% vs 8.1%, P = .002) (Figure 2A ). Among ESRD subjects, lower cTfh proportion and lower absolute numbers were observed in patients on dialysis when compared to patients who were not yet receiving replacement therapy (4.8% vs 8.2%, P = .012, and 81.8 cel/uL vs 152.9 cel/ uL, P = .005, respectively) ( Figure 2B,C) . Moreover, time in dialysis The production of IgG was accordingly higher in cultures with CD4+CXCR5+ cells than with CD4+CXCR5-cells, both in healthy controls (P < .001) and ESRD patients (trend). IgG measurements were higher in cultures from healthy controls than from ESRD patients (P = .03). *P < .05; ***P < .001
seemed to correlate with a gradual diminishing of CD4+CXCR5+
( Figure 2D and Figure S1A ) and CD4+CXCR5+CCR7loPD1hi cell numbers ( Figure S1B ). Although fewer cTfh were observed in ESRD patients, these cells maintained a capacity to differentiate B cells into plasmablasts similar to controls ( Figure 1C ). However, plasmablasts from ESRD patients produced less IgG than those from controls.
| Effect of induction therapy on cTfh
During the posttransplantation follow-up, cTfh increased in the overall group of patients. When we analyzed the cohort according to the induction therapy received, we observed that the profile of cTfh posttransplantation in basiliximab-treated patients was very similar to that of patients without induction therapy ( Figure 2E ). In particular, the cTfh count at month 6 posttransplant was double the pretransplantation cTfh count in both basiliximab-treated (9.4 cel/uL vs 4.2 cel/uL, P < .001) and no-induction patients (11.6 cel/uL vs 6.6
cel/uL, P = .018). On the contrary, in thymoglobulin-treated patients there was a striking reduction in cTfh numbers soon after the administration of the induction therapy (3.35 cel/uL pretransplantation vs 0.03 cel/uL at day 7, P < .001). cTfh numbers in thymoglobulin-treated patients also increased over time posttransplant but remained lower than in the basiliximab and no-induction groups at every time point.
At month 6, the cTfh numbers in the thymoglobulin-treated group were similar to pretransplantation (3.5 vs 3.35 cel/uL, P = .59).
Thus, thymoglobulin drastically eliminated cTfh, taking 6 months for these cells to recover, whereas basiliximab had no depleting effect on cTfh.
| cTfh are increased pretransplantation in recipients with previous exposure to alloantigens and in HLA-sensitized recipients
We analyzed the relationship between cTfh and previous exposure to alloantigens in patients in the waiting list. In our cohort, 10.2% of patients received a second renal allograft. This group of patients who had received a previous renal transplant (and had therefore been exposed to alloantigens from the previous donor)
showed a higher pretransplantation cTfh frequency than the recipients of a first allograft (1.7% vs 0.8%, P = .025) ( Figure 3A ).
Second kidney recipients also had higher pretransplantation cTfh absolute numbers, although not significantly different than first transplant patients ( Figure 3B ). Patients who had had blood transfusions (39.3% in our cohort) showed increased cTfh compared to nontransfused recipients (1% vs 0.7%, P = .018) ( Figure 3C ).
Women with a previous pregnancy did not show higher Tfh counts (data not shown).
Thus, in our cohort, patients who received transfusions or a previous kidney graft showed augmented cTfh. Exposure to alloantigens drives the production of anti-HLA antibodies, so we asked whether, before transplantation, higher numbers of cTfh could be related to anti-HLA sensitization. cTfh were increased pretransplantation in patients with anti-HLA class I antibodies vs nonsensitized patients, although this comparison did not reach statistical significance (1.2% vs 0.8%, P = .1). Because women have lower cTfh than men ( Figure S2) , and there was a higher proportion of women within the sensitized group (51.2% vs 24.5% in the nonsensitized group), we analyzed the association between pretransplant cTfh and anti-HLA sensitization separately in men and women. We found higher cTfh numbers in women with anti-HLA class I antibodies than in nonsensitized women (9.2 cel/uL vs 3.5 cel/uL, P = .23) ( Figure 3D ), and this difference reached significance when comparing cTfh frequencies between those groups (1.7% vs 0.8%, P = .026) ( Figure 3E ).
We did not find this association between cTfh and anti-HLA class II antibodies ( Figure S3A,B) . Moreover, a positive correlation was found between frequencies of cTfh and levels of anti-HLA class I antibodies ( Figure 3F ). These data suggest a role of Tfh for the production of anti-HLA antibodies in patients with contact to alloantigens before transplantation.
| cTfh are associated with de novo anti-HLA antibody production in renal transplanted patients
We studied cTfh numbers in patients who were not anti-HLA sensitized pretransplantation. Unsensitized recipients were divided depending on whether they developed de novo anti-HLA antibodies during the one-year clinical follow-up (-/+ group, 7%) or not (-/-group, 93%). As already noted, cTfh increased with time posttransplant in both groups (P < .001); however, patients who developed de novo anti-HLA antibodies showed a significantly higher expansion of cTfh than recipients remaining anti-HLA-negative (P < .05) ( Figure 4A ,B).
This result was not due to differences in induction treatment between the groups, because the proportion of patients with no induction, basiliximab, or thymoglobulin was similar in -/+ or -/-patients (P = .13). Interestingly, we observed a positive correlation between cTfh frequencies pretransplantation and the intensity of de novo anti-HLA class I and II antibodies ( Figure 4C,D) . No association was found between cTfh frequencies pretransplantation and de novo DSA ( Figure S3C,D) .
F I G U R E 2 Low cTfh in ESRD and dialysis patients and effect of induction therapy. (A) cTfh were lower in patients with ESRD vs healthy controls (HC) (P = .002). (B)
Patients who received dialysis as replacement therapy had decreased cTfh proportion (P = .012) and (C) decreased cTfh absolute numbers (P = .005) when compared to patients in predialysis. (D) Inverse correlation between cTfh absolute numbers and time in dialysis (P < .001). (E) cTfh augmented within the first 6 months after transplantation; however, patients who received thymoglobulin had significantly lower numbers of cTfh than basiliximab-treated patients or patients without induction. There were barely no cTfh at +7 and +14 days posttransplantation in the thymoglobulin-treated group. cTfh in basiliximab-treated patients did not differ from those receiving no induction. *P < .05; **P < .01; ***P < .001
The development of de novo anti-HLA antibodies posttransplantation suggests cTfh activity despite maintenance immunosuppression. We tested the capacity of cTfh from transplanted patients to differentiate B cells into plasmablasts in vitro. Circulating CD4+CXCR5+ obtained from patients 6 months after transplantation were able to derive IgG-producing plasmablasts. However, cultures from patients produced less IgG than those from healthy controls (P = .021) ( Figure 4E ,F and Figure S4 ). This reduced function of patients' cTfh could be because of the immunosuppressive maintenance therapy patients received.
| Higher cTfh are associated with acute rejection in renal transplantation
Because we found a relationship between higher cTfh and pretransplantation or de novo anti-HLA sensitization, and because anti-HLA antibodies enhance the risk for rejection, we assessed the association between cTfh and acute rejection. In our cohort, 18 patients (8.7%) experienced BPAR. Pretransplantation count of cTfh was positively associated with BPAR risk (HR = 1.14 (1.04-1.25), P < .01). Thus, BPAR was 1.14 times more likely to occur per each increase of 1 cTfh per microliter as measured before transplantation.
| D ISCUSS I ON
Tfh have been extensively studied in the fields of autoimmunity, vaccines, and infection, where they have been shown to be crucial for the production of either aberrant or protective antibodies.
9-14
However, little is known about the role of Tfh in humoral alloimmunity. With the discovery of circulating Tfh, 8 the analysis of Tfh properties in humans has become more accessible. In the present paper we have confirmed, as others before, 13, 17, 18 that circulating CD4+CXCR5+ include cells functionally similar to Tfh in secondary lymphoid organs, in that they direct the differentiation of B cells into plasmablasts able to secrete immunoglobulins. This was not the case when we cocultured non-cTfh (CD4+CXCR5-) with memory B cells.
We found cTfh were decreased in ESRD patients compared to healthy controls. Commonly, patients waiting for a renal transplant suffer uremia-associated immunodeficiency with lymphopenia and impaired immune function of T cells and other immune cells. 20 Our F I G U R E 3 Patients exposed to alloantigens had increased cTfh pretransplantation and augmentation of cTfh correlated with anti-HLA class I antibody intensity. (A) Patients who received a second renal transplant had higher frequency of cTfh pretransplantation than patients receiving their first renal transplant (P = .025). (B) There was also a trend toward increased cTfh numbers in retransplantation patients. (C) Patients who had had previous blood transfusions also showed increased pretransplant cTfh (P = .018). (D) There was a trend toward higher absolute numbers of cTfh in female patients who had pretransplant anti-HLA class I antibodies compared to nonsensitized female patients. (E) Sensitized women had higher frequency of pretransplant cTfh than nonsensitized women (P = .026). (F) There was a positive correlation between cTfh and anti-HLA class I antibody levels within the group of highly HLA-sensitized patients (P = .005). *P < .05 patients had low lymphocyte count (data not shown), which could explain the reduction in absolute numbers of cTfh. However, they also had a reduction in the proportion of cTfh, which means that the cTfh subpopulation is more acutely reduced than other cell subsets within the lymphocyte compartment. This finding suggests that the proinflammatory environment and oxidative stress associated with The observed gradual increase of cTfh during the 6 months after transplantation could reflect recovery from uremia, because of the new functional kidney, or recovery from the potential depletion effect of dialysis. Remarkably, cTfh numbers increased in the presence of the usual immunosuppressive maintenance therapy. We observed that, although to a lesser extent than control cTfh, patient cTfh at 6 months posttransplant were able to differentiate immunoglobulin-producing plasmablasts, despite being exposed to immunosuppressive therapy. Whether this difference is significant or not remains to be further investigated.
Regarding induction therapy, we found that thymoglobulin drastically reduced cTfh count in the early posttransplantation period and it took 6 months for cTfh cells to recover to pretransplantation level.
On the contrary, basiliximab, a nondepleting antibody that blocks IL2 receptor, had no reducing effect on cTfh count. Moreover, basiliximab- high-risk recipients. 24 Further studies on the effect of basiliximab on Tfh will be useful to assess its utility in avoiding humoral alloresponses against the graft.
cTfh have been found to expand after effective vaccination or after infection. [25] [26] [27] We therefore hypothesized that previous exposure to alloantigens could increase cTfh in patients in the waiting list. Patients with past kidney transplant or blood transfusions showed higher cTfh pretransplantation. The expansion of cTfh in these patients may reflect allospecific responses not only directed against HLA but also against minor histocompatibility antigens, together with responses against environmental and pathogenic stimuli. In particular, patients with a previous transplant are commonly infected with Citomegalovirus and Candida albicans, and up to 10% of the T cell repertoire can be specific for these infections. 28, 29 Further studies on the T-cell receptor repertoire to analyze the composition of the expanded population would be of interest.
Previous exposure to alloantigens is considered a risk factor in transplantation through the production of anti-HLA antibodies. In our cohort, we failed to demonstrate a statistical association between cTfh and presence of anti-HLA antibodies in male recipients and in anti-HLA class II sensitized recipients, probably because of the low number of subjects in these patient groups. However, women with pretransplant anti-HLA antibodies had higher cTfh and there was a direct correlation between cTfh frequency and intensity of anti-HLA antibody production.
Based on the expansion of cTfh in chronic viral infections, [30] [31] [32] we speculated that permanent contact with antigens from the allograft could stimulate the expansion of the cTfh pool posttransplant, which would translate into production of alloantibodies. Indeed, transplanted patients who developed de novo anti-HLA antibodies had higher cTfh numbers posttransplantation. A similar finding was published by
Chenouard et al, who reported higher cTfh counts at 1-year posttransplantation in stable renal transplant patients subsequently developing de novo DSA. 15 In our cohort, we did not observe an association between cTfh and DSA as the number of patients who developed de novo DSA was very low. Finally, we found that pretransplantation numbers of cTfh were associated with BPAR with a significant HR of 1.14. Thus, we show here for the first time that higher cTfh levels are a risk factor and Rebeca Pena for their technical help. We also thank all patients who contributed to the study.
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